Search
for
Sort by
Research
180-210 / 1000+ resultsresearch Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma
Adverse events from vismodegib can be managed effectively to ensure optimal treatment.
research Tufted hair folliculitis in a woman treated with trastuzumab
Trastuzumab may cause tufted hair folliculitis as a side effect.
research PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands
PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
research Health Canada has approved finasteride [Proscar; Merck Frosst] and doxazosin cotherapy
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment
Photodynamic therapy improved skin issues from sorafenib when other treatments failed.
research Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.
research ANALYSIS OF ADVERSE DRUG REACTIONS (ADRs) AND THEIR SEVERITY IN BREAST CANCER PATIENTS TREATED WITH THE DOCETAXEL-DOXORUBICIN REGIMEN AT SULTAN AGUNG ISLAMIC HOSPITAL
Most adverse reactions to the treatment were mild, with nausea being the most common.
research Capture of endothelial cells under flow using immobilized vascular endothelial growth factor
A surface with VEGF can specifically capture endothelial cells from flowing fluids.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research IMMUNOTHERAPY OF CANCER: IMMUNE CHECKPOINT BLOCKERS, VACCINES AND ADOPTIVE T CELL THERAPIES
Enhancing immune response can improve cancer treatment effectiveness.
research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
research Fabrication and in vitro evaluation of silk fibroin-folic acid decorated paclitaxel and hydroxyurea nanostructured lipid carriers for targeting ovarian cancer cells: A double sword approach
The new drug carriers show promise for better targeting and treating ovarian cancer.
research The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.
Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research Results of Ifosfamide Combination Chemotherapy in Patients with Advanced Soft Tissue Sarcomas
Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.
research Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.
research Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
research pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer
The nano-carrier makes etoposide safer and more effective against lung cancer.
research Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
research Fractional microporation-guided delivery of nanoencapsulated drugs for enhanced cutaneous and follicular absorption: a comparison of ablative laser and radiofrequency microneedling
research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
research 566 Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity
ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Combination of Western Medicine and Traditional Chinese Medicine for Treatment of Malignant Bone and Soft Tissue Tumors
Combining Western chemotherapy with Traditional Chinese Medicine can reduce side effects and improve immune response in treating bone and soft tissue tumors.